Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Eyenovia Inc (EYEN) COM USD0.0001

Sell:$2.99 Buy:$3.00 Change: $0.08 (2.60%)
Market closed |  Prices as at close on 22 May 2020 | Switch to live prices |
Change: $0.08 (2.60%)
Market closed |  Prices as at close on 22 May 2020 | Switch to live prices |
Change: $0.08 (2.60%)
Market closed |  Prices as at close on 22 May 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Eyenovia, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of micro-doses therapeutics products utilizing the patented piezo-print delivery technology. Eyenovia’s pipeline is focused on the late-stage development of microdosed medications for mydriasis, myopia progression, glaucoma, and other eye diseases. MicroStat is a combination micro-formulation product (phenylephrine-tropicamide) candidate for pharmacologic mydriasis (eye dilation). MicroPine is topical treatment for progressive myopia, a back-of-the-eye disease. MicroProst is latanoprost formulation product candidate, which is being developed for the reduction of IOP in patients with Chronic Angle Closure Glaucoma (CACG), as well as Primary Open Angle Glaucoma (POAG) and Ocular Hypertension. MicroTears is a micro-droplet ocular hyperemia (red eye), pruritis (itch) and ocular lubrication product.

Contact details

295 Madison Ave Ste 2400
United States
+1 (813) 7669539

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$59.33 million
Shares in issue:
19.78 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Fredric Eshelman
    Independent Chairman of the Board
  • Sean Ianchulev
    Chief Executive Officer, Director, Chief Medical Officer
  • John Gandolfo
    Chief Financial Officer
  • Michael Rowe
    Vice President of Marketing
  • Jennifer Clasby
    Vice President - Clinical Operations
  • Luke Clauson
    Vice President - Research &Development; and Manufacturing

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.